Anti-Coagulants - Angola

Angola

The Anti-Coagulants market in Angola is expected to witness a significant growth in revenue, with projections indicating a figure of US$8.04m in 2024.
Furthermore, it is estimated that the market will experience a continuous annual growth rate (CAGR 2024-2029) of 7.42%, leading to a market volume of US$11.50m by 2029.
Interestingly, when compared globally, United States is anticipated to generate the highest revenue in this market, with a staggering amount of US$16,740.00m in 2024.
Angola is experiencing a growing demand for anti-coagulants due to an aging population and an increase in cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Angola is experiencing steady growth in recent years.

Customer preferences: Angolan customers are increasingly seeking out anti-coagulant medications due to the rising incidence of cardiovascular diseases and stroke. Additionally, the aging population in Angola is also contributing to the growing demand for anti-coagulants.

Trends in the market: The market for anti-coagulants in Angola is expected to continue growing due to the increasing prevalence of cardiovascular diseases and stroke. Furthermore, the government's efforts to improve healthcare infrastructure and access to medication are also expected to drive growth in the market.

Local special circumstances: Angola is a country with a high burden of non-communicable diseases such as cardiovascular diseases and stroke. This is due to factors such as a lack of physical activity, unhealthy diets, and high rates of smoking. As a result, there is a growing need for medications such as anti-coagulants to manage these conditions.

Underlying macroeconomic factors: The Angolan economy has been growing steadily in recent years, which has led to an increase in disposable income among consumers. This has allowed more people to afford medications such as anti-coagulants. Additionally, the government's efforts to improve healthcare infrastructure and access to medication are also contributing to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.